newsfilter
← Latest News
Business Wire·

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

– Acquisition of potentially best-in-class dopamine agonist combination product candidates, including ALTO-207, expands precision psychiatry pipeline; guided by compelling PAX-D study results published in The Lancet